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Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with o5% survivors after
5 years. High expression levels of ADAM8, a metalloprotease disintegrin, are correlated with
poor clinical outcome. We show that ADAM8 expression is associated with increased
migration and invasiveness of PDAC cells caused by activation of ERK1/2 and higher MMP
activities. For biological function, ADAM8 requires multimerization and associates with b1
integrin on the cell surface. A peptidomimetic ADAM8 inhibitor, BK-1361, designed by
structural modelling of the disintegrin domain, prevents ADAM8 multimerization. In PDAC
cells, BK-1361 affects ADAM8 function leading to reduced invasiveness, and less ERK1/2 and
MMP activation. BK-1361 application in mice decreased tumour burden and metastasis of
implanted pancreatic tumour cells and provides improved metrics of clinical symptoms and
survival in a KrasG12D-driven mouse model of PDAC. Thus, our data integrate ADAM8 in
pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.
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P
ancreatic ductal adenocarcinoma (PDAC) has the highest
mortality rate of solid organ cancers with a 5-year
survival rate o5% (ref. 1). This cancer type is remarkably
homogenous in that 95% of PDAC originate from oncogenic
mutations in the KRAS gene. Hence, representative authentic
mouse models of PDAC with pancreas-speciﬁc expression of Kras
have been generated2. In mice and man, KRAS mutations cause
early-stage pancreatic intraepithelial neoplasias (PanINs) with
subsequent development of progressive PDAC. A hallmark of
PDAC is the massive inﬁltration of tumour cells into the pancreas
and surrounding tissues including lymphatic organs, spleen and
peritoneum, and the concomitant metastasis to the liver and
lungs3–6. Inﬁltration of pancreatic tumour cells depends critically
on extracellular matrix (ECM) remodelling7,8. Given the
importance of the ECM in PDAC, the proteolytic release of
membrane proteins (shedding) as well as ECM (e.g., collagens
and ﬁbronectin) degradation has previously been postulated to
have a pivotal role in shaping the tumour microenvironment9,10.
Members of the Metzincin superfamily, matrix metalloproteases
(MMPs) and/or ADAM (A disintegrin and metalloproteinase)
proteases have been described in these processes11. In particular,
the contribution of ADAMs to extracellular remodelling12 and
tumour growth, inﬁltration, metastasis and angiogenesis by
shedding of membrane-associated proteins may be
important9,13,14. In PDAC patient samples, elevated expression
levels of ADAM8 (CD156a, MS2) have been identiﬁed versus
normal pancreatic tissues. In normal pancreas, ADAM8
expression is very low and restricted to the plasma membrane
of ductal cells and, to a lesser extent, of islets and acinar cells. In
PDAC tissues, ADAM8 is strongly expressed in tubular
complexes and in cancer cells. Based on clinical data, high
ADAM8 expression levels are associated with a poor patient
prognosis, resulting in reduced survival and increased metastatic
spread15.
ADAM8 is a proteolytically active member of the ADAM
protease family originally described in inﬂammatory processes16–18
and subsequently in many systems of the body19. Increased
expression of ADAM8 was observed in other neoplasias, such as
high-grade glioma20, lung adenocarcinoma21, prostate cancer22
and, more recently, in squamous head and neck cell carcinoma23,
medulloblastoma24, osteosarcoma25 and breast cancer26,
suggesting that ADAM8 has an active role in tumour
progression. Thus, understanding the functional role of ADAM8
in tumour biology is important.
ADAM8 is localized in a few distinct cell types and the analysis
of ADAM8-deﬁcient mice inferred dispensability for normal
development and homeostasis27,28. ADAM8 is typically expressed
at low levels, giving rise to the current hypothesis that it is
functionally irrelevant for homeostasis unless induced by
inﬂammatory stimuli17 or neoplasias. Once upregulated,
ADAM8 can overlap with the substrate spectrum of ADAM10
and ADAM17, two major shedding enzymes, and cleave proteins
with immune functions such as tumour necrosis factor receptor 1
(ref. 28), L-selectin29, CD23 (ref. 30) and CXCL1 (ref. 31), as well
as cell adhesion proteins such as CHL1 (ref. 32), thereby
potentially modulating immune response or cell adhesion.
Cleavage of other ADAM8 substrates such as Tie-2, Flt-1,
VE-cadherin, Flk-1, EphB4, KL-1, CD31 and E-selectin33 or by
cleavage of ﬁbronectin12 may control tumour angiogenesis.
Moreover, a role for ADAM8 in metastases34 and in cell
invasiveness15,20,22 has been postulated, although the
mechanism underlying these processes is unknown.
ADAM8 is activated by autocatalysis in the trans-Golgi
network35 and, unlike other ADAMs, not by furine-like
convertases. For in vivo activity, ADAM8 requires homophilic
multimerization of at least two ADAM8 monomers on the cell
membrane. This speciﬁc interaction of ADAM8 monomers offers
a potential strategy for blocking ADAM8 activity by preventing
ADAM8 multimerization in vivo. We have demonstrated
previously that ADAM8–ADAM8 interactions critically depend
on the disintegrin (DI)/cysteine (DC)-rich domain35.
In addition, ADAM family members can bind to integrins
in vitro via their DC-rich domains36; as prototype, human
ADAM15 contains a canonical RGD motif in the integrin-
binding loop (IBL) of the DI domain37. However, even for non-
RGD containing ADAMs such as ADAM9, integrin binding was
demonstrated. ADAM9 binding to b1 integrin causes migration
of melanoma cells38, and for ADAM8, binding to a9b1 was shown
in osteoclast turnover39, suggesting that these ADAM–integrin
interaction have functional relevance.
Although ADAM8 has been associated with increased tumour
cell migration, invasiveness and metastasis via a combination
of catalytic, adhesion and cell signalling functions15,20, no
mechanistic data on ADAM8 in tumour progression and
speciﬁcally in PDAC are available. Here we provide evidence
for an involvement of ADAM8 in cancer signalling and in
tumour progression. Furthermore, we validate ADAM8 as a
target in PDAC by introducing a speciﬁc ADAM8 inhibitor.
Results
ADAM8 inhibition strategy. Cellular activation of ADAM8
occurs in two steps. The ﬁrst is intracellular prodomain removal
in vesicles, whereas the second is metalloprotease (MP) domain
removal from membrane-bound-activated ADAM8 (Fig. 1a).
Autocatalysis implies that ADAM8 multimerizes (Fig. 1a), and
that the ADAM8 DC-rich domain is critical for multimerization
as demonstrated previously by using an antibody directed against
the DC domain35. To deﬁne the regions in the DC domain
involved in ADAM8–ADAM8 interactions, homology modelling
of the ADAM8 DC domain was performed based on the
ADAM10 sequence derived from Janes et al.40 (Supplementary
Figs 1 and 2). We hypothesized that an extended loop structure
exposing the RGD-like positions of the ‘KDX’ motif in the IBL in
human and mouse ADAM8 might be responsible for the
observed interactions (Fig. 1b).
In mouse and human ADAM8, the amino-acid residues K and
D are exposed towards the outer aspect of the DI domain, thereby
forming a potential contact interface (Fig. 1b, labelled in
magenta). To generate a peptidomimetic compound, a series of
cyclic peptides (six amino acids) mimicking the motif ‘RLSKDK’
of mouse ADAM8 in the IBL were generated. Amino acids R, L or
S were inserted in the peptide as D-amino acids to alter the
conformational constraint of the KDK motif and to generate a
potentially more stable peptide for in vivo work. The cyclic
peptide sequence RLsKDK with ‘s’ as D-serine named BK-1361
was most effective in blocking ADAM8-dependent cell adhesion
in mouse and human cells with similar efﬁciencies
(Supplementary Fig. 3) and ADAM8–ADAM8 interactions as
shown by reduced FRET (Fo¨rster resonance energy transfer)/
FLIM (ﬂuorescence lifetime imaging) efﬁciency. In contrast, a
control peptide (CP; RLsADK; Fig. 1c) had no effect.
Multimerization of ADAM8 was investigated by native gel
electrophoresis (Fig. 1d). Under native conditions, 100 ng of pro-
ADAM8 associates in dimeric (B120 kDa) and trimeric (B180
kDa) complexes of pro-ADAM8, while in the presence of BK-
1361, only monomers (B60 kDa) were detected (Fig. 1d, left
panel). Detection of dimers and trimers suggests that dimers
associate by DI domain (homophilic) interactions, whereas
trimers could be formed by a different mode of interaction. At
higher concentrations of recombinant ADAM8, we detected even
larger complexes as a result of greater order multimerization
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(Supplementary Fig. 3e) in agreement with more than one
interaction mode that results in ADAM8 complex formation.
These interactions can be blocked by BK-1361, and we further
analysed whether prevention of complex formation affects
ADAM8 activity in vitro.
Activation of pro-ADAM8 was detected over a time course of
120 h (Fig. 1d, right panel) but blocked by BK-1361 (Fig. 1d, bar
graph) with an IC50 of 120±19 nM. In a cell-based assay, BK-
1361 and other peptides (Table 1) were tested for their ability to
inhibit ADAM8-dependent extracellular resulting in an active
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Figure 1 | Extracellular ADAM8 processing and inhibition of ADAM8 activity. (a) ADAM8 processing: (1) autocatalytic prodomain (red) removal for
active ADAM8 (2); after membrane transport, ADAM8 cleaves membrane proteins (3a); alternatively, removal of a soluble MP (blue) domain (3b) leads to
ECM cleavage and formation of remnant ADAM8. A putative interaction site (magenta) located in the disintegrin (DI) domain (green). (b) Homology
modelling of ADAM8 DC-rich domain based on homology to pdb ﬁle 2ao7 (ref. 41) within the IBL region of ADAM15. The amino-acid motif ‘KD’ is
potentially accessible to peptidomimetics such as BK-1361 (Table 1). (c) FRET analysis of ADAM8 monomers in the presence of BK-1362 (control peptide,
CP) and BK-1361 (500nM) in Panc1 cells. FLIM (in nanoseconds, ns) and FRETefﬁciency are calculated from412 cells in three independent experiments.
ANOVA was used as statistical test; data are presented as mean±s.e.m.; *Po0.05 (Student’s t-test). (d) Left panel, complex of pro-ADAM8 (100 ng per
lane) at 0 and 24h analysed by native gel electrophoresis and immunoblotting. With CP, pro-ADAM8 forms complexes (dimers and trimers, arrowheads 2
and 3); with BK-1361, only monomers of pro-ADMA8 are detected (arrowhead 1); right panel, activation of recombinant pro-ADAM8 in vitro in the
presence of CP and BK-1361. Bar graph: Autocatalytic activation of pro-ADAM8±BK-1361 (200nM) in vitro. Pro-ADAM8 (100 ng) incubated for indicated
times; Fluorescence activity using CD23 ﬂuorogenic peptide monitored over 5 days in triplicates. FU, ﬂuorescence units. (e) Effect of BK-1361 and CPs
(Table 1) on ADAM8 MP domain removal in ADAM8-BiPro-transfected COS7 cells after 12 h. Anti-BiPro antibody detects pro (triangle), mature (circle)
and remnant (diamond) ADAM8 in cell lysates (WCLs); soluble ADAM8 activity from processed ADAM8 is detected in cell supernatants (SNs) by CD 23
peptide cleavage. (f) Test of BK-1361 for membrane-bound CD23 in WCLs and soluble CD 23 (sCD23) in SNs. Cells were incubated with CP or BK-1361
(500nM) for 12 h; ctrl, control; LC, loading control. (g) Dose-dependent inhibition of CD23 shedding determined by ELISA (n¼ 5) with mean values±s.d.;
IC50 value for BK-1361 was 182±23 nM, whereas CP shows no signiﬁcant inhibition of CD23 shedding. ADAM8-mCherry, ADAM8-mCh.
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soluble MP domain (Figs 1a and 3b). In cell lysates, presence of
the remnant form indicates cellular processing of ADAM8 as seen
with no or inactive CPs (Fig. 1e, upper panel). In cell
supernatants (SNs), processing results in detectable activity of
released ADAM8 MP. BK-1361, but not other BK peptide
variants, decreased this activity (Fig. 1e, lower panel). BK-1361
blocks mouse and human ADAM8 in vitro with similar
efﬁciencies, a prerequisite for testing BK-1361 in orthotopic
PDAC models using human donor cells in mouse hosts.
We next tested BK-1361 and variants for their ability to inhibit
shedding of CD23, a known substrate of ADAM8 (ref. 30) in cell-
based shedding assays (Fig. 1f and Table 1). Co-transfection of
ADAM8 with a tagged CD23 construct in COS7 cells resulted in
signiﬁcant shedding of CD23 as soluble 21 kDa fragment
(sCD23); sCD23 was detectable in SNs when ADAM8 was co-
expressed. In the presence of 500 nM BK-1361, sCD23 was
undetectable, demonstrating that BK-1361 inhibits the in vivo
shedding activity of ADAM8. Enzyme-linked immunosorbent
assay (ELISA) assays were performed to determine [sCD23]
versus [BK-1361] with an IC50 of 182±23 nM for BK-1361; BK-
1362 had no signiﬁcant effect (Fig. 1g). We conclude that BK-
1361 affects ADAM8–ADAM8 interactions, thereby inhibiting
cellular shedding and autocatalytic activation of ADAM8 in vitro
and in a cell-based assay in a speciﬁc manner, as neither catalytic
activities of ADAM9, -10, -12 and -17 nor MMP-2, -9 and -14
were inhibited in concentrations of up to 10 mM (Table 2).
ADAM8 induces migration/invasion of pancreatic cancer cells.
As shown earlier, ADAM8 expression is correlated with inva-
siveness in vitro in various cell lines15,20,21. However, no
functional in vivo data on ADAM8 in pancreatic malignancies
are yet available. To establish cell lines for analysis of PDAC
in vivo, we selected Panc1 (very low ADAM8) and AsPC-1 cells
(high endogenous levels of ADAM8) as determined by western
blotting15 (Fig. 2a). Panc1 cell lines with a moderate
overexpression of ADAM8 (Panc1_A8; NM_001109.4; Fig. 2b)
and AsPC-1 cell lines with ADAM8 shRNA knockdown
constructs were generated. Microarray analysis of Panc1_ctrl
versus Panc1_A8 cells revealed that Panc1_A8 cells showed no
off-target effects of the ADAM8 knockdown, as expression levels
of 495% of genes were unchanged, including genes encoding
MMPs, other ADAMs, ADAMTS and TIMP1–4 levels
(Supplementary Fig. 4). Cellular localization of ADAM8,
analysed by confocal laser-scanning microscopy, conﬁrmed low
ADAM8 expression in Panc1_ctrl cells compared with enhanced
ADAM8 expression in Panc1_A8 cells. In Panc1_A8 cells,
ADAM8 is localized in the cell membrane and membrane
extrusions (Fig. 2b). In SNs of different Panc1_A8 cell clones
characterized (n¼ 30), ADAM8 catalytic activity correlated with
the ADAM8 dosage, determined by western blotting (Fig. 2c) and
CD23 ﬂuorescence assay (Fig. 2d). Migration and invasion
behaviour of Panc1_ctrl cells was compared with Panc1_A8
cells in vitro (Fig. 2e,f). In wound-healing (scratch) assays,
migration rates of Panc1_A8 cells were signiﬁcantly increased
(8±3.8-fold) compared with Panc1_ctrl cells. Panc1_A8 cell
migration is inhibited by BB-94, a MP inhibitor. In addition,
application of BK-1361 reduced migration rates of Panc1_A8 cells
signiﬁcantly, but not to the same level as BB-94, suggesting that
ADAM8 modulates other MP activities accounting for migration
above control levels. Accordingly, invasion into different ECM
substrates such as collagen I, collagen IV, ﬁbronectin and
Matrigel was enhanced by ADAM8 (Fig. 2f).
ADAM8 increases extracellular MMP activity. A proteolytic
activity matrix assay (PrAMA)41 was used for simultaneous
detection of multiple activities in Panc1_ctrl and Panc1_A8 cells
that could account for the observed invasiveness. Brieﬂy, PrAMA
is based on the knowledge of individual FRET-substrate MMP/
ADAM cleavage signatures using puriﬁed enzymes41. Panels of
FRET-substrate cleavage measurements can be used to infer a
dynamic, quantitative and speciﬁc proﬁle of MMP/ADAM
proteolytic activities from complex enzyme mixtures such a SNs
and solubilized membranes (see Methods and Supplementary
Fig. 5). PrAMA inference revealed increased activities of MMP-2
in SNs and MMP-14 (MT1-MMP) in cell membranes of
Panc1_A8 cells compared with Panc1_ctrl cells (Fig. 2g and
Supplementary Fig. 5). Enhanced ADAM8 activities were
detected in SNs and membranes of Panc1_A8 cells. Gelatine
zymography and western blotting for MMP-2 and MMP-14
conﬁrmed increased activity of MMP-2 and higher membrane
concentration of MT1-MMP (Fig. 2h). However, elevated MMP
activities in Panc1_A8 cells are not due to transcriptional
activation of MMP-2 and MMP-14 (Supplementary Fig. 4).
We further investigated whether BK-1361 is able to affect
ADAM8-dependent invasiveness and MMP secretion of
Panc1_A8 cells (Fig. 2i,j). BK-1361 and peptide variants were
tested for their ability to block invasiveness of Panc1_A8 cells
(Fig. 2i). A dose-dependent effect of BK-1361 on invasion of
Table 1 | ADAM8 inhibition by hydroxamates and cyclic
peptides.
Inhibitor A8 activation:
IC50 (nM)
CD23 shedding:
IC50 (nM)
Hydroxamates
BB-94 (batimastat) 46±4.5 57±6
BB-2516 (marimastat) 1,054±154 1,250±103
Peptide inhibitors
cyclo-RLsKDK (BK-1361) 120±19 182±23
cyclo-RlSKDK (BK-1451) 478±24 570±23
cyclo-rLSKDK (BK-2351) 1,979±143 2,430±87
RLSKDK (BK-1351) 410,000 410,000
cyclo-RLsADK (BK-1362) 45,000 410,000
cyclo-RLsKAK (BK-1363) 45,000 45,000
cyclo-RLsKDA (BK-1364) 165±34 255±27
ADAM8, a disintegrin and metalloproteinase 8.
IC50 values of peptide variants tested for A8 inhibition in vitro and for inhibition of CD23
shedding. Recombinant A8 (100 ng total protein) was incubated for 24 h with the respective
inhibitors/peptides in a concentration of 20–10,000 nM. A8 activity was monitored using the
CD23 ﬂuorescence assay described in the Methods section.
Table 2 | Speciﬁcity of BK-1361 against other ADAM
proteases and MMPs.
Protease Peptide substrate IC50
(nM)
ADAM8 Dabcyl-His-Gly-Asp-Gln-Met-Ala-Gln-Lys-Ser-
Lys(Fam)-NH2*
120±19
ADAM9 Dabcyl-Leu-Ala-Gln-Ala-Homophe-Arg-Ser-
Lys(Fam)-NH2*
410,000
ADAM10 Dabcyl-His-Gly-Asp-Gln-Met-Ala-Gln-Lys-Ser-
Lys(Fam)-NH2*
410,000
ADAM17 Dabcyl-Leu-Ala-Gln-Ala-Homophe-Arg-Ser-
Lys(Fam)-NH2*
410,000
MMP-2 Mca-PLGL-Dpa-AR-NH2 410,000
MMP-14 Mca-KPLGL-Dpa-AR-NH2 410,000
ADAM, a disintegrin and metalloproteinase; MMP, matrix metalloproteases.
Inhibition analysis of ADAM and MMP proteins using different concentrations of BK-1361.
*Substrates as described in Moss and Rasmussen, 59. Concentration of BK-1361 up to 10 mM did
not result in signiﬁcant inhibition of MMP and ADAM proteins except for ADAM8.
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Figure 2 | Effect of ADAM8 expression in Panc1 cells. (a) Western blotting (WB) of ADAM8 in PDAC cell lines Panc1, Capan-1 and AsPC-1. (b) ADAM8
immunoﬂuorescence (anti-ADAM8, green) in non-permeabilized Panc1_ctrl and Panc1_A8 cells. ADAM8 membrane staining in Panc1_ctrl (upper panel)
and Panc1_A8 (lower panel) cells. Insert (lower panel), ADAM8 localization in membrane protrusions. Scale bar, 50mm. (c) WB of whole-cell lysates
(WCLs) and supernatants (SNs) from Panc1_ctrl and Panc1_A8 cells; proform (arrowhead), mature (circle) and remnant form (diamond) of ADAM8,
respectively. In Panc1_A8 SN, anB30-kDa soluble ADAM8 MP fragment is detectable (ﬁlled arrowhead). (d) ADAM8 activities in SNs of Panc1_ctrl and
Panc1_A8 cells were measured as ﬂuorescence units (FU; n¼ 5) by cleavage of CD23 substrate; ***Po0.0001 (Student’s t-test); rel, relative. (e) Scratch
assay of Panc1_ctrl versus Panc1_A8 cells treated either with BB-94 (100nM ‘þ ’ and 1mM ‘þ þ ’) or with BK-1361 (200nM ‘þ ’ and 500nM ‘þ þ ’). Cell
counts after t¼0 and 12 h (three independent experiments in triplicates, n¼ 9); ANOVA was used as statistical test; *Po0.01, **Po0.001 (Student’s
t-test). (f) Invasion of Panc1_ctrl and Panc1_A8 cells in collagen I (Coll I), collagen IV (Coll IV), ﬁbronectin (FN) and Matrigel (MG) analysed in Boyden
chambers (18 h). Data are presented as mean±s.d. from ﬁve independent experiments. ANOVA test was used. *Po0.01, ***Po0.0001 (Student’s t-test).
(g) PrAMA inference analysis of SNs and membranes (Mem) from Panc1_ctrl and Panc1_A8 cells using ﬁve ﬂuorogenic peptides to detect MMP activities.
Activities of MMP-2, MMP-14 and ADAM8 are shown as relative changes to Panc1_ctrl. (h) WB and gelatine zymography of Panc1_ctrl and Panc1_A8 SNs
for MMP-2, MMP-2 activity and MMP-14. (i) Invasion of Panc1_A8 cells treated with BK-1361 (10, 100 and 1,000nM) or 1,000nM CPs for 6 h (Table 1).
Invasion was determined after 18 h. ANOVA test was used. *Po0.005, **Po0.001, ***Po0.0001. (j) PrAMA from Panc1_A8 cells treated with vehicle,
BK-1361, BB-94 and U0126 (1mM, each) for 24 h. Values are given relative to Panc1_A8 treated with vehicle only. ANOVA was used as statistical test.
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Panc1_A8 cells was observed. From CPs, only BK-1364 had a
slight effect on invasion. In parallel, we performed PrAMA assays
in Panc1_A8 cells to evaluate MMP-2, MMP-14, and ADAM8
activities in the presence of BK-1361, BB-94 and the extracellular
regulated kinase (ERK) inhibitor U0126, respectively (Fig. 2j).
BK-1361 and BB-94 reduced activities of MMP-2, MMP-14 and
ADAM8. ERK inhibition had a slight effect on MMP-2 activity
and a greater effect on MMP-14 activity, whereas ADAM8
activity was not affected. These ﬁndings argue for an ERK1/2-
mediated effect on MMP-14, and, to a lesser extent, on MMP-2
activation. ADAM8 as regulator of ERK1/2 activation is not
directly affected by U0126.
Our data suggest an effect of pharmacological ADAM8
inhibition on invasiveness of PDAC cells. To determine the
effect of a genetic ADAM8 knockdown on cellular invasiveness,
we selected AsPC-1 cells with high endogenous ADAM8 levels
(Fig. 2a) and generated AsPC_1 cell clones carrying a stable
knockdown of ADAM8 (sh_A8). Three representative cell clones
from different sh_A8 constructs were analysed for ADAM8
expression (Fig. 3a–c), cell migration and invasion (Fig. 3d,e and
Supplementary Movies 1, 2). Knockdown of ADAM8 in AsPC-1
cells caused a signiﬁcant drop in cell migration depending on the
gene dosage of ADAM8. Invasion of AsPC-1 cells was similarly
affected by ADAM8 dosage (Fig. 3e). BK-1361 treatment of wild-
type (wt) AsPC-1 cells was similar to the genetic knockdown of
ADAM8 with 87±3.5% inhibition (Fig. 3f). PrAMA assays were
performed with AsPC-1_shCtrl±BK-1361 and AsPC-1_shA8
cell clones 1 and 2 (Fig. 3g). Reduction of MMP-2 and MMP-14
activities were observed in AsPC-1_shA8 clones. In BK-1361-
treated AsPC-1_shCtrl cells, MMP-2 was similarly affected,
however, the effect on MMP-14 was less pronounced (Fig. 3g).
ADAM8 interacts with integrin b1 in pancreatic cancer cells.
The membrane localization of ADAM8 in Panc1_A8 cells sug-
gests that ADAM8 is complexed with cellular integrins, thereby
enhancing cell migration and invasiveness. To investigate this,
co-immunoprecipitation (co-IP) experiments were performed in
Panc1 cells expressing either control or a tagged ADAM8 con-
struct (ADAM8-BiPro). As a result, b1 integrin, present in
comparable amounts in Panc1_ctrl and Panc1_A8 cells, was
co-IP with ADAM8 (Fig. 4a–c). To analyse cellular ADAM8-b1
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integrin and ADAM8–ADAM8 interactions, FRET/FLIM ana-
lyses were performed to detect FRET in cell lines expressing
fusion proteins ADAM8-GFP and ADAM8-mCherry, respec-
tively. ADAM8 multimerization was detected in Panc1 cells
(Fig. 4d,e), indicated by FRET efﬁciency of 7.5±0.93%. In cells,
complex formation and membrane localization of ADAM8
in vivo involves b1 integrin, since treatment of Panc1 cells with a
b1 integrin-blocking antibody (Fig. 4d,e) resulted in a signiﬁcant
drop to 3.1±0.8% FRET efﬁciency. Moreover, MDA-MB-231
breast cancer cells lacking b1 integrin (Fig. 4f,g) show a signiﬁcant
change in cellular morphology while ADAM8 localization in
lamellipod structures is lost. Interestingly, administration of BK-
1361 causes a similar change in cell morphology (Fig. 4h,i). We
conclude that b1 integrin knockdown or speciﬁc ADAM8 inhibi-
tion have similar effects on ADAM8 membrane localization
(Fig. 4j). In addition, areas of positive ADAM8-FRET in MDA-MB-
231 cells were analysed for b1 integrin (Fig. 4k,l). In most areas,
activated b1 integrin was detected by antibody 12G10, suggesting
that ADAM8 interaction and b1 integrin activation are correlated.
To analyse whether ADAM8 interactions cause altered
intracellular signalling, a mitogen-activated protein kinase
(MAPK) array was used to screen for kinase phosphorylation
in Panc1_ctrl and Panc1_A8 cells (Supplementary Fig. 6). As
potential downstream effectors of the observed ADAM8-b1
integrin interaction, we investigated phosphorylation of focal
adhesion kinase (FAK), ERK1/2, Akt and p38c in Panc1_A8
versus Panc1_ctrl cells. Focal adhesion kinase was described as b1
integrin interacting protein42. In western blots, increased
phosphorylation of FAK at residue Tyr397 correlates with
ADAM8 expression levels in Panc1 cells (Fig. 5a). In addition
to pFAK, we detected increased phosphorylation of ERK1/2 (p44/
p42) in Panc1_A8 cells by western blotting using corresponding
phospho-speciﬁc antibodies (3.4-fold±0.2 Panc1_A8 versus
Panc1_ctrl; Fig. 5b). The observed increase in pERK1/2 was
reduced in Panc1_A8 cells treated with BK-1361 (Fig. 5b). To
correlate ERK1/2 phosphorylation with the observed invasiveness
of Panc1 cells, Matrigel invasion assays were performed in the
presence of U0126 (Fig. 5c). U0126 blocked ERK1/2
phosphorylation in Panc1_ctrl and Panc1_A8 cells, and resulted
in decreased invasion of Panc1_A8 cells. In addition, AsPC-
1_shCtrl and three AsPC-1_shA8 cell clones with different
ADAM8 levels were analysed for pERK1/2 levels (Fig. 5d). In cell
clone AsPC-1_shA8/2, pERK1/2 levels were reduced by 2.9±0.3
fold, suggesting that ADAM8 expression levels are correlated with
pERK1/2. In AsPC-1 cells, ADAM8 levels affect MEK1/2, p-Akt
and c-Raf activation (Fig. 5e). In addition, a b1 integrin antibody
that blocks activation was able to reduce pERK1/2 levels in
Panc1_A8 cells, demonstrating that b1 integrin is required for
ADAM8-dependent ERK1/2 activation (Supplementary Fig. 7).
To investigate whether the observed FAK and ERK1/2
activation depends on membrane-bound ADAM8, Panc1 cells
were transfected with wt ADAM8 (A8 wt), an ADAM8 construct
lacking the cytoplasmic domain (A8DCD), or a soluble ADAM8
(A8ecto) construct (Fig. 5f). First, we conﬁrmed that all constructs
are catalytically active, as all three ADAM8 proteins shed CD23
(sCD23) from the cell membrane. Interestingly, neither DCD nor
the ectodomain of ADAM8 were able to activate FAK and ERK1/2
(Fig. 5f), suggesting that intracellular signalling mediated by
ADAM8 requires membrane localization of ADAM8 and the
presence of the cytoplasmic domain. As potential substrates for
ERK activation, that is, the epidermal growth factor receptor
(EGFR) ligand family such as Heparin-binding epidermal growth
factor (HB-EGF), EGF or amphiregulin, were screened
(Supplementary Fig. 8). We have not identiﬁed signiﬁcant EGFR
ligand release, so that ADAM8–b1 integrin interactions might act
independent from EGFR signalling.
Role of ADAM8 in PDAC and effect of BK-1361 in vivo. Based
on our ﬁndings that ADAM8 inhibition blocks invasiveness and
ERK1/2 signalling in PDAC cells, we used BK-1361 to validate
ADAM8 as a therapeutic target in PDAC in vivo. Initially, acute
and chronic toxicity analyses were performed in C57BL/6J mice.
In single and repeated dose applications, doses of up to 10mg g 1
body weight were well tolerated as mice showed no abnormalities,
weight loss or motor performance over 4 weeks. After necropsy,
organs investigated showed no abnormalities at histological level
(Supplementary Fig. 9). Owing to the lack of acute and chronic
toxicity, a dose of 10mg g 1 body weight was applied daily for
subsequent in vivo applications.
Initially, orthotopic injections of Panc1 cells into mouse
pancreas were performed (Fig. 6a–g) in three cohorts (n¼ 12
each); cohort 1 received Panc1_A8 cells, cohort 2 received
Panc1_ctrl cells and cohort 3 received Panc1_A8 cells followed by
daily intraperitoneal injection of 10mg g 1 BK-1361. Mice were
monitored for 12 days, by which time most of the mice injected
with Panc1_A8 cells were moribund and reached end point
criteria. In contrast, mice injected with Panc1_ctrl cells or
Panc1_A8/BK-1361 treatment showed improved clinical para-
meters. At end point, pancreatic tumours formed from Panc1_ctrl
cells were signiﬁcantly smaller than from Panc1_A8 cells
(Fig. 6a,b). Moreover, tumours obtained from mice that received
Panc1_A8 cells and daily injections of BK-1361 were signiﬁcantly
smaller. These data indicate that inhibition of ADAM8 reduced
tumour load to almost the value of Panc1_ctrl-derived tumours
(0.42 g for Panc1_ctrl versus 0.62 g for Panc1_A8/BK-1361). By
histology, a signiﬁcant invasion of Panc1_A8 cells into the
pancreatic tissue was detected, whereas in tumours derived from
Panc1_A8/BK-1361 cells, tumour masses embedded in Matrigel
were primarily localized to the implantation site even after 12
days, as the boundaries of pancreas and implanted tumour mass
were still distinct (Fig. 6c). In addition, there were signs of
necrosis inside the implanted tumour treated with BK-1361
(Fig. 6c), inferring that non-invasive Panc1 cells undergo necrotic
changes. Moreover, ADAM8 levels in Panc1_ctrl cells located in
the tumour were increased under hypoxic conditions. Co-staining
for pERK1/2 was observed in inﬁltrative ADAM8-positive
tumour cells (Fig. 6d, upper panel).
Metastasis and inﬁltration is the major cause for the observed
morbidity in PDAC5,6. Since ADAM8 was discussed in the
context of inﬁltration and metastasis26,34, we investigated
orthotopic mice for inﬁltration of close structures such as
peritoneum, diaphragm and spleen, and liver metastasis. From
mice injected with Panc1_A8 cells, we found signiﬁcant
inﬁltrates in adjacent organs (Fig. 6e,f). Macroscopic inspection
and haematoxylin/eosin stain of tissue sections revealed
higher invasion into spleen and diaphragm of Panc1_A8-
injected mice (Fig. 6e). Analysis of inﬁltration areas showed
enhanced invasive behaviour of Panc1_A8 cells versus Panc1_ctrl
and Panc1_A8/BK-1361 cells (Fig. 6f) in peritoneum, diaphragm
and spleen.
ADAM8 staining of liver sections revealed occurrence of
micrometastases with higher frequencies in Panc1_A8 implanted
mice compared with Panc1_ctrl and Panc1_A8/BK-1361
(Fig. 6g). Metastases frequencies were markedly different between
Panc1_A8, Panc1_ctrl and Panc1_A8/BK-1361. Furthermore, the
implantation of AsPC-1_shCtrl and AsPC-1_shA8 cells was
analysed (Fig. 6h). AsPC-1_shCtrl cells caused large streams of
tumour cells invading the pancreatic tissue with an inﬁltration
area of 21±2.8%. In contrast, AsPC-1_shA8 cells were located
close to the injection site and showed less invasive behaviour with
inﬁltration areas of 3.4±1.2% (Po0.01). Thus, data derived from
genetic ADAM8 knockdown support the results obtained with
ADAM8 inhibition using BK-1361.
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The therapeutic effect of ADAM8 inhibition in vivo was
analysed in mice with genotype KrasLSL-G12D, Trp53R172H/þ ,
PdxCre/þ (KPC)2, a genetically engineered PDAC mouse model.
Injections of BK-1361 were started around the onset of PanINs.
KPC control groups received injections of either saline (as in a
clinical setting) or CP (BK-1362). Control groups showed
progression to PDAC with a median survival of 15.5 weeks for
saline and 16 weeks for BK-1362. In contrast, BK-1361-treated
KPC mice have extended median survival times of 24.2 weeks
(Fig. 7a). The in vivo efﬁcacy of BK-1361 was demonstrated by
determining soluble ADAM8 levels (Fig. 7b). Lower frequencies
of metastases in liver and lung were observed in BK-1361-treated
KPC mice (Fig. 7c). Pancreas morphology in BK-1361-treated
mice showed reduced inﬁltration areas in the pancreas compared
with control mice (Fig. 7d,e), while the areas of intact acinar
structures are increased (0.74% for BK-1361-treated versus
0.18% for saline-treated mice, Fig. 7f). Tumour progression
was associated with increased staining for ADAM8 and pERK1/2
in control KPC mice. In BK-1361-treated KPC mice, ADAM8
and pERK1/2 staining is restricted to acinar structures, suggesting
that despite occurrence of neoplasias, tumour inﬁltration was
reduced while the acinar architecture was more conserved
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Figure 5 | ADAM8 intracellular kinase signalling. (a) Antibody detection of FAK phosphorylation (Y397) in Panc1_A8 and Panc1_ctrl cells 24 h after
plating cells on plastic. Total FAK antibody was used to control equal loading and anti-ADAM8 conﬁrms ADAM8 expression. A b-tubulin antibody was
used as loading control. Note a 2.8-fold increase in pFAK in Panc1_A8 cells compared with Panc1_ctrl cells. (b) Western blotting (WB) of relative (rel.)
phosphorylation of ERK1/2, in Panc1_ctrl and Panc1_A8 cells as determined by antibodies directed against phosphorylated forms of respective kinases.
Lower panel, ERK1/2 phosphorylation in Panc1_ctrl and Panc1_A8 cells in the presence of 500 nM BK-1361. (c) Relative invasiveness of Panc1_ctrl and
Panc1_A8 cells (in duplicates) in the presence of ERK1/2 inhibitor U0126 (10mM) after 18 h incubation, indicating a strong correlation between ERK1/2
phosphorylation and invasion in Panc1 cells. ANOVA statistical test was used; *Po0.01, **Po0.001 (Student’s t-test). (d) Correlation of ADAM8 and
pERK1/2 levels in AsPC-1 control (shCtrl) and knockdown (shA8) cells. In clone AsPC-1_shA8/2, levels of pERK1/2 are reduced by threefold. (e) Relative
kinase phosphorylation of the ERK and AKTsignalling pathways after 18 h incubation with (þ ) or without ( ) U0126 (10 mM) in protein lysates of AsPC-
1_shCtrl and AsPC-1_shA8 cells. Kinases and their respective phosphorylation sites are indicated on the right. (f) Membrane-bound ADAM8 with
cytoplasmic domain is required for FAK and ERK1/2 activation. Panc1 cells were transiently transfected with full-length ADAM8 construct (A8 wt),
ADAM8 lacking the cytoplasmic domain (A8DCD), or with a construct encoding the soluble ectodomain (A8ecto) of ADAM8, respectively. To control for
cellular ADAM8 activity, the amount of soluble CD23 was determined in SNs by using an HA-tag antibody. The presence of ADAM8 protein variants,
relative levels of pFAK and pERK1/2 were detected by WB, using b-tubulin as loading control. Levels of FAK and ERK phosphorylation were quantiﬁed from
three independent experiments, given as mean±s.e.m. WCL, whole-cell lysates.
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box 2: enlarged view of the border between implantation site and surrounding ductal tissue; box 3: signs of intratumoral necrosis in tumours treated with
BK-1361 (scale bars, 100mm). (d) pERK1/2 staining of tumours. Only for Panc1_A8 (top), tumour cells stain positive for pERK1/2 (scale bar, 100mm). (e)
Morphology of spleen and diaphragm from mice injected with either Panc1_A8, Panc1_ctrl, or Panc1_A8/BK-1361. In PAS stains (lower panel), inﬁltration of
tumour cells in the diaphragm is only seen in Panc1_A8. Scale bars, 100mm. (f) Quantiﬁcation of inﬁltration areas in peritoneum, diaphragm and spleen.
Values are in % of total tissue area±s.e.m. (n¼ 12). (g) ADAM8þ micrometastases in livers from Panc1_A8-injected mice; in contrast, metastases (mets)
were mostly absent in livers from Panc1_ctrl and Panc1_A8/BK-1361-treated mice (scale bar, 200mm); relative frequency (Freq.) of liver metastases in mice
injected with Panc1_A8, Panc1_ctrl and Panc1_A8/BK-1361, respectively (n¼ 12). (h) Pancreas histology (PAS, ADAM8 IHC) after orthotopic implantation
of AsPC-1_shCtrl and AsPC-1_shA8/2 cells. Scale bar, left upper panel, 100mm. ADAM8þ cells in pancreas injected with AsPC-1_shCtrl cells, weaker
staining with AsPC-1_shA8 cells. Inﬁltration areas in pancreata from six mice per group were quantiﬁed. Mean±s.e.m. **Po0.01 (Student’s t-test).
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(Fig. 7g). Staining intensities of pERK1/2 and ADAM8 is reduced
in BK-1361-treated KPC mice (Fig. 7h), suggesting that, in vivo,
ADAM8 inhibition leads to reduced activation of pERK1/2.
Discussion
Our study links the available clinical data on ADAM8 expression
in pancreatic cancer cell lines and in PDAC15 to mechanistic data
on ADAM8 in PDAC tumour progression. Using a novel proof-
of-concept ADAM8 inhibitor, we demonstrate that ADAM8
inhibition in PDAC leads to reduction of tumour load, inﬁltration
and metastasis in vivo by affecting downstream signalling of
ADAM8, thus further supporting the important role of ADAM8
in PDAC.
ERK1/2 signalling is considered a major pathway in PDAC,
and the EGF/EGFR pathway has been established as an
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Figure 7 | Application of peptide BK-1361 in PDAC mice. (a) Kaplan–Meier analysis of KPC/saline, KPC/BK-1362 (CP) and KPC/BK-1361 mice
(n¼ 10 in each group). Median survival times (MSTs) are given in the diagram; statistical analysis was carried out using a log-rank test with Po0.001.
(b) Concentration of soluble ADAM8 (sADAM8) in normal mouse pancreas (wt) and in pancreata of saline-treated and BK-1361-treated KPC mice, as
determined by ELISA (n¼ 5) in ngmg 1 from pancreas. ANOVA was used as statistical test. *Po0.01, **Po0.001. (c) Frequency (Freq.) of metastases
(mets) in liver and lung of KPC/control and KPC/BK-1361 mice. (d) IHC of mice at week 12. Representative Periodic Acid Schiffs (PAS) staining in
KPC/saline versus KPC/BK-1361 pancreas; scale bar, 200mm. (e) Whisker plot with quantiﬁcation of invasive PDAC in saline and BK-1361-treated KPC
mice. Tukey-type analysis was used for statistics; **Po0.001 (Student’s t-test). (f) Whisker plot of normal acinar area in KPC/saline and KPC/BK-1361-
treated pancreata (n¼ 5), Tukey-type analysis, *Po0.05 (Student’s t-test). (g,h) PAS staining, ADAM8 and pERK1/2 IHC in KPC/control (g) and
KPC/BK-1361 (h) mice. Arrowheads indicate focal acinar cell staining, arrow indicates nuclear staining and asterisks mark identical positions. Note loss of
ductal architecture in control versus BK-1361-treated mice with positive staining for ADAM8 and pERK1/2. Quantiﬁcation of IHC for KPC/saline and
KPC/BK-1361 pancreas reveals less staining for pERK1/2 in BK-1361 versus saline-treated pancreata. Tukey-type statistical analysis was performed.
**oPo0.001 (Student’s t-test). Scale bar in d, 100mm.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7175 ARTICLE
NATURE COMMUNICATIONS | 6:6175 | DOI: 10.1038/ncomms7175 | www.nature.com/naturecommunications 11
& 2015 Macmillan Publishers Limited. All rights reserved.
upstream effector of ERK1/2, so that PDAC development and
progression is associated with overexpression of EGFR ligands
and ADAM17 (refs 43,44). Aberrant EGF signalling is associated
with ERK1/2 signalling in tumour proliferation and migration of
pancreatic cancer cells45. Since ADAM8 is an active shedding
enzyme, evidence of a function of ADAM8 in EGF/EGFR
signalling was investigated. No ADAM8-dependent shedding
of EGFR ligands such as EGF, epiregulin, amphiregulin and
HB-EGF was detected in substrate screens (Supplementary
Fig. 8). This suggests that ADAM8 could act independent from
the EGF/EGFR pathway, as demonstrated for ADAM10 and
ADAM17 (ref. 14). Thus, it is likely that ADAM8 stimulates non-
EGFR pathways for PDAC progression, which is in agreement
with recent experimental observations that progression of PDAC
is beyond sole EGF function46. For this hypothesis, we provide
experimental evidence by demonstrating a link between ADAM8
and ERK1/2 signalling.
Our data suggest that ADAM8 interacts with b1 integrin, an
essential signalling module in PDAC47. The b1-associated
signalling pathways involving kinases such as FAK, p38, Akt
and ERK1/2 are altered by expression of ADAM8. In particular,
ERK1/2 activation is correlated with ADAM8 levels, as shown for
cells either overexpressing ADAM8 or AsPC-1 cells bearing a
genetic ADAM8 knockdown. In accordance with potent effects of
ERK1/2 inhibitors PD98059 and U0126 on reducing Panc1 cell
invasion, we propose an ADAM8-induced ERK1/2 activation via
the ADAM8 cytoplasmic domain, thereby regulating MMP
activities more effectively than inhibitors for Akt and p38.
Although ADAM8 can cleave ﬁbronectin12, the effect of
ADAM8 on cell migration into different ECM substrates could
better be explained by ERK1/2 activation in Panc1 cells that
regulates the extracellular activities of MMPs. In accordance,
increased extracellular activities of MMP-2 and MMP-14 were
detected by PrAMA assays. MMP-2 was shown to promote
PDAC signiﬁcantly48,49, and MMP-2 inhibitors were exploited in
Panc1-derived xenografted tumours, resulting in reduced tumour
load50. Moreover, the role of MMP-14 has been investigated in
PDAC and its role in invasion into collagen I, the most abundant
ECM present in human PDAC, and its role in cancer invasion has
been demonstrated8. MMP-2/ MMP-14 induction, however, was
not detected on transcriptional levels (Supplementary Fig. 4).
Thus, ADAM8-dependent kinase activation such as FAK and
ERK1/2 may increase the release of MMP-2 and MMP-14,
respectively. To support this notion, FAK and ERK1/2 were
shown to regulate MMP release51,52. MMP-9 is undetectable in
Panc1 cells, so that the effect of FAK and ERK1/2 on MMP
release is restricted to MMP-2 and MMP-14, respectively. Their
activities are interlinked as pro-MMP-2 activation and MMP-14
processing are concomitant events53.
Xenograft data demonstrate that ADAM8 causes increased
invasiveness and tumour growth in vivo. In cell culture, serum-
dependent and -independent growth of Panc1 cells was not
affected, suggesting that the observed growth relates to inﬁltrative
growth. It is interesting to note that in the orthotopic PDAC
model, non-invasive Panc1 cells (Panc1_ctrl or Panc1_A8 cells in
mice treated with BK-1361) showed intratumoral hypoxia and
necrosis. Hypoxia stimulates ADAM8 expression in a range of
PDAC cell lines and Panc1 cells weakly in culture54; however,
our data demonstrated a strong induction of ADAM8 under
hypoxic conditions in vivo. It is likely that ADAM8 stimulates
angiogenesis under hypoxic conditions, as shown earlier in a
model of retinopathy34.
It is remarkable how signiﬁcantly ADAM8 contributed to
tumour cell invasion and metastasis in the PDAC models.
Consistent with a proposed role of ADAM8 in PDAC progres-
sion, we performed a chemotherapy study in KPC mice by
initiating BK-1361 treatment at the onset of PanINsB4 weeks of
age2. Given the high degree of speciﬁcity reported for BK-1361
towards ADAM8 (see Table 2 for details), it is likely that BK-1361
has selectivity for ADAM8 over other ADAM proteases.
However, since BK-1361 mimics an integrin-binding motif, off-
target effects may exist and could act on integrins, in particular on
b1 integrin. In this respect, unwanted side effects of BK-1361 by
inhibition of non-tumour cell located in b1 integrin should be
excluded. However, our in vivo data in PDAC mice suggest that
off-target effects by BK-1361 may not affect the therapeutic
beneﬁt, given the prolonged survival of KPC mice treated with
BK-1361 (median survival 15.5 weeks for saline versus 24.2 weeks
for BK-1361-treated KPC mice). In terms of percentage survival,
ADAM8 inhibition in KPC mice was similarly effective as
EGFR inhibition by erlotinib/gemcitabine combination therapy43,
considering the stringency of the PDAC model used. For further
clinical trials, a combination therapy might be beneﬁcial with
potentially additive effects of an ADAM8 inhibitory and an
anti-EGFR therapy.
Our in vitro studies demonstrated that ADAM8 activity
requires dimer or greater order multimerization. As reported
for ADAM12 and ADAM17, complex formation revealed
ambiguous results, similar to our observations of ADAM8 dimers
and trimers that were detectable in native gels. However, the
precise mechanism of higher order aggregate formation remains
to be elucidated and a number of domains have been implied in
this process55,56. From the literature, different aggregation
mechanisms of domains functionally also present in ADAM8
have been proposed and there may be several modes of
interaction55,56. We hypothesize that these interactions may
occur sequentially, as the ADAM8 DI domain interaction,
blocked by BK-1361 prevents further complexes from forming.
Since we detected dimers and trimers in the native gel at low
concentrations of recombinant ADAM8, we interpret these data
that dimers are formed by DI domain interactions, whereas
trimers could be formed by different interactions involving the
EGF-like domain, as a model for ADAM17 multimerization
proposes55. Indeed, high concentrations of ADAM8 in vitro lead
to higher order multimers such as aggregates of two dimers and/
or two trimers, thereby suggesting the presence of such
interactions apart from the DI domain interactions
(Supplementary Fig. 3e). Given the effect of BK-1361 on
preventing any ADAM8–ADAM8 interactions, we conclude
that initial dimer formation is a critical step in ADAM8
multimerization so that all higher aggregates are prevented
from forming by BK-1361. For most ADAM family members,
modelling of their DI domains revealed a so-called C-fold
scaffold57 that is inaccessible at the position of the IBL, as shown
in the X-ray structure for ADAM10 (ref. 41). Homology
modelling of the ADAM8 DI domain based on ADAM10
structural data reveals that the IBL is signiﬁcantly shifted
towards an extended loop structure as this was shown for
ADAM28 (ref. 58). Initial proof for the functionality of ADAM8-
binding peptides was obtained by blocking homophilic
interactions in cell-binding assays36 with EC50 values in the low
nanomolar range using BK-1361 and derived peptides. Since
there is no homologous amino-acid sequence in the IBL of other
ADAM proteases, our approach combines the advantage of high
speciﬁcity with little or no off-target effects as judged by the lack
of toxicity of BK-1361. In conjunction with no expected side
effects of ADAM8 inhibition as deduced from ADAM8-deﬁcient
mice28,29, ADAM8 inhibition might be an effective therapy
option in mouse PDAC that accurately mirrors human pathology.
As ﬁrst-in-class inhibitor, BK-1361 is structurally similar to
cilengitide, an av integrin-binding angiogenesis inhibitor that
raised no safety issues in patients, and is orally available but failed
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in phase III trials owing to unwanted side effects. Even a short
in vivo half-life ofB34min for BK-1361 (Supplementary Fig. 10),
comparable to the half-life of cilengitide, should not limit the
therapeutic use of BK-1361, and thereby provides a platform for
further preclinical studies including alternative delivery routes
and structure-activity relationship.
Methods
Mice. KrasLSL G12D;Trp53R172H/þ ;PdxCre/þ (KPC) were described earlier2.
After weaning, all mice were genotyped. Equal numbers of male and female mice
were taken for analysis. All animal experiments were conducted in accordance with
Home Ofﬁce regulations under a relevant project licence (T.H.) and with the
German Law on the protection of animals, and were approved by the Local
Government (Regierungspra¨sidium Giessen, J.W.B.).
Cell lines. Panc1 and AsPC-1 cells were obtained from Sigma (UK); HEK-293,
COS7 and MDA-MB-231 cells were purchased from American Type Culture
Collection (ATCC). AsPC-1 cells were grown in RPMI medium; all other cell lines
were grown in DMEM (Dulbecco’s-modiﬁed Eagle medium, Invitrogen, Gronin-
gen, The Netherlands), with all media containing 10% fetal calf serum, 1% peni-
cillin/streptomycin and 1% glutamine (Invitrogen, UK). For all experiments, cells
were kept in humidiﬁed atmosphere at 37 C/5% CO2.
Antibodies. Human recombinant ADAM8 ectodomain (1031-AD), recombinant
ADAM9, ADAM10 and ADAM17, and MMP-2 and MMP-14, human phospho-
MAPK Array Kit (ARY002B) and Proteome Proﬁler soluble receptor array
(ARY012) were obtained from R&D Systems (Abingdon, UK). For simultaneous
detection of mouse and human ADAM8, a rabbit polyclonal antibody was pur-
chased from Biorbyt (orb 4376, 1:1,000). For IP and native gel electrophoresis, an
antibody against the ectodomain of ADAM8 (R&D Systems, AF1031, 1:1,000) was
used, for detection of human ADAM8 in western blots, we used an antibody
against the cytoplasmic domain of ADAM8 (AB19017; Millipore, Watford, UK,
1:1,000). MMP-2 (R&D Systems, 1;1,000), MMP-9 (Genetex, Irvine, USA, 1:2,000),
MMP-14 (R&D Systems, 1:1,000), Birch pollen proﬁlin (BiPro 4A6, Antibody
Facility, Braunschweig University, Germany, 1:2,000) and integrin b1 (sc-8978;
Santa Cruz Biotechnology, USA, 1:500). Detection of CD23 was performed using
an anti-HA antibody (3F10, Mannheim, Germany, 1:1,000). Antibody 12G10
(Abcam, Cambridge, UK, 1:1,000) was used to detect activated integrin b1. For
blocking integrin b1, antibody P4C10 from Millipore (1:500) was used. Speciﬁc
antibodies against the phosphorylated forms of ERK1/2 (T202/Y204; Cell Signal-
ing, Hitchin, UK, 1:1,000), Akt (Ser473; Cell Signaling, 1:1,000 and Thr308; Cell
Signaling, 1:1,000), p38g (T180/Y182; R&D Systems, 1:1,000), Phophatase and
tensin homolog (PTEN) (Ser380, Cell Signaling, 1:1,000), c-Raf (Ser 259, Cell
Signaling, 1:1,000), MEK1/2 (Ser217/221, Cell Signaling, 1:1,000) and FAK (Y397;
BD Biosciences, Oxford, UK, 1:1,000) were used. Horseradish peroxidase (HRP)
conjugates antibodies were purchased from Sigma and Southern Biotech (both UK,
1:2,000) and ﬂuorescently labelled antibodies were obtained from Invitrogen and
Abcam (1:1,000). The inhibitor tablets cOmplete w/o EDTA and PhosSTOP were
purchased from Roche.
Peptides. Cyclic peptides (named BK-n) were synthesized by Peptide 2.0
(Canada). Purities were 497%. Peptide identities were veriﬁed by high-perfor-
mance liquid chromatography (HPLC) and mass spectrometry (MS).
Fluorescent peptides contain 5-carboxy-ﬂuoresceine (FAM) as ﬂuorophore and
Dabcyl ([4-((4-(dimethylamino)phenyl)azo)benzoic acid]) as a quencher59.
Dinitrophenyl-labelled peptides were purchased from the UNC Chapel Hill peptide
synthesis laboratory.
Oligonucleotides. Oligonucleotides for PCR and site-directed mutagenesis were
synthesized by Sigma.
Cloning of ADAM8 constructs. Full-length human ADAM8 cDNA was obtained
by reverse transcription and PCR (hA8fw 50-ATGCGCGGCCTCGGGCTCT-30 ,
hA8Sto.as 50-CTAGGGTGCTGTGGGAGCTCCG-30) from AsPC-1 cells. The PCR
product was cloned into the expression vector pTarget (Promega) and the
sequences of the ADAM8 constructs were veriﬁed by DNA sequencing. The
C-terminally tagged ADAM8 constructs (EGFP, mCherry and BiPro36) were
generated by PCR using cloning primers (hA8SgfI 50-GAGGCGATCGCCATGC
GCGGCCTCGGGCTC-30 , hA8MluI 50-GCGACGCGTGGGTGCTGTGGGAG
CTCC) and ligated into the pCMV6 expression vector (Origene) using the MluI
and SgfI restriction sites, respectively.
Transfection experiments. LTX Lipofectamine (Invitrogen) was used in cell
transfection assays according to the manufacturer’s instructions. Cells were lysed
48 h later in modiﬁed RIPA buffer (50mM HEPES pH 7.4, 150mM NaCl, 1%
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 10mM 1,10-phenanthroline,
cOmplete EDTA free and PhosSTOP) and sonicated. A Bradford assay (Thermo
Scientiﬁc) was used to determine the protein concentrations in whole-cell lysates
and in SNs.
Generation of Panc1_A8 cells. Panc1 cells were co-transfected with a full-length
ADAM8 construct (cloned in pTarget) and the pRFP-C-RS vector (Origene)
encoding for red ﬂuorescence protein (RFP). Control cells were transfected with
RFP vector only. Twenty-four hours after transfection, cells were treated with the
respective selection antibiotics (1 mgml 1 puromycin and 1mgml 1 G418).
Resistant RFP-positive cells were isolated by ﬂuorescence-activated cell sorting
(FACS). ADAM8 expression in single-cell clones was analysed by western blotting
and quantitative reverse transcription PCR.
Generation ADAM8 knockdown cells. AsPC-1 cells were stably transfected
with HuSH shADAM8 constructs (TF314948, Origene) with the target sequence
50-GCGGCACCTGCATGACAACGTACAGCTCA-30 and selected with
puromycin (1 mgml 1). Around 20 cell clones were selected and checked for
successful knockdown of ADAM8. To generate control cell clones, a construct with
a scramble shRNA sequence was used.
Quantitative PCR analysis. After reverse transcription using 1mg of total RNA,
quantitative PCR was performed using SYBR Green kits (Bioline, Luckenwalde,
Germany) in a STEP-One Light cycler (ABI Systems, Weiterstadt, Germany). As a
housekeeping control gene, acidic ribosomal gene XS13 was used. The primers were
as follows: ADAM8: fw: 50-ACAATGCAGAGTTCCAGATGC-30 ; rev: 50-GGACCA
CACGGAAGTTGAGTT-30 ; XS13: 50-TGGGCAAGAACACCATGATG-30 ; rev:
50-AGTTTCTCCAGAGCTGGGTTGT-30 .
ADAM8 ELISA. To determine soluble ADAM8 in mouse tissue, a commercial
ADAM8 ELISA assay (Hoelzel Diagnostica, Cologne, Germany) was used
according to the manufacturer’s instructions. Pancreas tissues were homogenized
in 10 volumes of ice-cold PBS containing 1mM ethylene glycol tetraacetic acid
(EGTA) and cOmplete Inhibitor Mix (Roche), clariﬁed by centrifugation
(10,000 r.p.m., 10min at 4 C). SNs were used for ELISA.
In vitro autocatalysis assay with ADAM8. Inactive recombinant human
ADAM8 (Met1-Pro497) was obtained from R&D Systems. ADAM8 autocatalytic
activation assays were performed in 50mM Tris, 10mM CaCl2 and 150mM NaCl,
pH 7.5 (TCN) buffer for the indicated times at 37 C. If applicable, peptides
were diluted 1:1,000 in the assay. To avoid evaporation during longer incubation
periods, the enzyme solutions were overlaid with mineral oil.
Native gel electrophoresis. To assess complex formation of recombinant
pro-ADAM8, native gel electrophoresis was performed. Samples were dissolved in
native buffer to retain protein complexes (0.02% b-glycerophosphate, 0.02%
sodium orthovanadate, 0.04% EGTA, 0.6% HEPES, 0.03% EDTA, 0.58% sodium
chloride, 1.5% dodecyl maltoside and 0.11% sodium pyrophosphate decahydrate;
Abcam) with 100 ng pro-ADAM8 in the presence of either 200 nM CP (BK-1362)
or BK-1361 were prepared and run on a 4–16% native gel (Novex, Life
Technologies, Darmstadt, Germany). As molecular weight marker, Novex Native
Mark was used. Gels were blotted and stained with AF1031 (see antibody section).
Activity assays with ADAM8. Activity of recombinant ADAM8 catalytic/DI
domain was monitored at 2min intervals using the ﬂuorescent substrate Dabcyl-
HGDQMAQKSK(5FAM)-NH2 (ref. 59), emulating the cleavage site of CD23, a
physiological substrate for ADAM8 (Fourie et al.30). Assays were performed in a
multiwell plate reader (Fluostar Optima, BMG Labtech, Offenburg, Germany)
using an excitation wavelength of 485 nm and an emission of 530 nm, with activity
expressed as ﬂuorescence units per hour. The substrate concentration was 10 mM in
assay buffer (20mM Tris, pH 8.0, 10mM CaCl2 and 6 10 4 % Brij-35).
Reactions were run in a 96-well black-coated plate. The concentration of ADAM8
enzyme was typically 10 ng per reaction. For inhibition assays using the cyclic
peptide inhibitor, concentrations varied from 10 nM up to 5 mM.
Determination of MMP/ADAM activities in PDAC cell lines. PrAMA analysis42
was performed as follows: Panc1, AsPC-1 cells and derivates were cultured in
duplicate using a six-well plate for 24 h in serum-free DMEM medium without
phenol red. Medium was removed, spun to remove cell fragments and set aside for
assaying. Cells were washed with PBS and then scraped from the plate and
resuspended in a 1.5-ml tube in a cold solution of 0.25M sucrose, 50mM Tris, pH
8, and a protease inhibitor mixture (cOmplete, Roche Applied Science). Cells were
broken via pipetting up and down, and the suspension was spun at 13,000 g to
pellet the membranes, which were resuspended and washed with sucrose buffer.
After pelleting, membranes were resuspended in 200 ml of sucrose buffer per well of
cells. Protein concentrations were determined using the Bio-Rad BPA assay. The
medium and membrane suspension were tested for MMP/ADAM activity by using
the PrAMA analysis technique developed by Miller et al.41 using substrates
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PEPDab005, PEPDab010, PEPDab008, PEPDab013 and PEPDab014, which varied
in their speciﬁcities towards different ADAM family members and MMPs. Brieﬂy,
12.5 mM substrate concentrations in 60 ml of assay buffer (see above) were
incubated with either 20 ml of medium or 10ml of resuspended membranes.
Fluorescence units versus time were monitored with a Fluostar BMG Optima using
excitation and emission wavelengths of 485 and 530 nM, respectively. Speciﬁc
protease activities were inferred with PrAMA by comparing the pattern of substrate
cleavage rates for each sample to a matrix of known substrate speciﬁcities for
ADAM8, ADAM10, ADAM17, MMP-2 and MMP-14 that were determined using
puriﬁed enzymes (Miller et al.41). Before performing PrAMA, substrate cleavage
rates were ﬁrst converted to fold change over control measurements as indicated.
Each PrAMA experiment was repeated three times and values for activities are
given as relative to deﬁned control measurements (a.u.).
Immunoﬂuorescence. MDA-MB-231, Panc1 cells and stable derivatives were
grown on coverslips, and were ﬁxed with 3.7% paraformaldehyde. ADAM8 was
detected in unpermeabilized cells by goat polyclonal antibody AF1031 (R&D
Systems) as primary antibody. As secondary antibody, we used goat-anti-rabbit-
Cy3 (1:500, Sigma). Images were acquired by confocal microscopy imaging using a
Nikon A1R microscope equipped with CFI Plan Fluor  40 oil objective. Images
were captured and exported with NIS Elements software (Nikon) and presented as
TIF ﬁles.
Immunoblotting and IP experiment. Equal amounts of protein were loaded onto
10% reducing polyacrylamide (PAA) gels. The proteins were transferred on
nitrocellulose, unspeciﬁc binding sites were blocked (5% skimmed milk, 0.1%
Tween-20 in PBS) and speciﬁc antibodies were used to detect the proteins of
interest. An enhanced chemiluminescent (ECL) substrate (Thermo Scientiﬁc) for
HRP enzyme and a chemiluminescence reader (Intas, Goettingen, Germany) were
used for visualization. Images in Figs 4 and 5 have been cropped for presentation.
Full size images are presented in Supplementary Figs 11 and 12.
For IP assays, the cells were lysed in co-IP buffer (50mM HEPES pH 7.4,
150mM NaCl2, 1% NP40, 0,5% sodium deoxycholate, 1,5mM MgCl2 and
cOmplete). The sonicated lysates were centrifuged two times at full speed to
remove cell debris. Cleared lysates were subjected to IP using speciﬁc antibodies in
concentrations of 0.2 mgml 1 (for anti-BiPro) and 2.5 mgml 1 (for anti-ADAM8)
overnight at 4 C. As unspeciﬁc binding controls, IgG was used instead of speciﬁc
antibodies. After binding of precipitated material to Protein-G-sepharose and
washing steps, the precipitated proteins were eluted by boiling in 2 SDS-loading
buffer and were analysed by western blotting.
Gelatine zymography. Protein samples were prepared in non-reducing sample
buffer without boiling before the experiment. Gelatin (0.1%) was added in a
separating gel to co-polymerize with PAA. During electrophoresis, proteins are
separated in the PAA gel, while SDS present in the gel preserves MMPs in an
inactive state. After the run, gels were washed with renaturing buffer (2.5% Triton
X-100; 2 30min each) that resulted in partially renatured MMPs with restored
activity. The gel was incubated in developing buffer (50mM Tris, pH 7.5, 200mM
NaCl, 4mM CaCl2 and 0.02% Brij-35; 30min at RT, followed by 24 h at 37 C in
fresh developing buffer). Next day, the gel was dyed in Coomassie staining buffer for
1 h followed by Coomassie destaining solution to visualize bands of active enzyme.
FRET/FLIM. FLIM was performed and data were analysed as described pre-
viously60. FLIM capability was provided by time-correlated single-photon counting
electronics (Becker & Hickl, SPC 700). Wideﬁeld acceptor monomeric Red
Fluorescent protein (mRFP) images were acquired using a CCD camera
(Hamamatsu) at exposure times of o100ms. Data were analysed using TRI2
software (developed by Dr Paul Barber). All histogram data are plotted as mean
FRET efﬁciency from412 cells per sample. Lifetime images of exemplary cells are
presented using a pseudocolour scale whereby blue depicts normal GFP lifetime
(that is, no FRET) and red depicts reduced GFP lifetime (areas of FRET). Each
experiment was repeated at least three times. Analysis of variance (ANOVA) was
used to test statistical signiﬁcance between different populations of data.
Activated MAPK assay. The human phospho-MAPK Array Kit (ARY002B; R&D
Systems) was used to analyse the inﬂuence of ADAM8 on the activation state of
altogether 26 MAPKs and other serine/threonine kinases. The assay was used
according to the manufacturer’s instructions. In brief, cells of the stable control
PANC1 clone and the ADAM8 overexpressing clone were lysed in lysis buffer 6,
sonicated and a Bradford assay was used to determine the protein concentrations.
Each array membrane was incubated in 2ml array buffer 5 for 1 h at room tem-
perature on a rocker. An amount of 1mg of each lysate was mixed with array buffer
1 to a ﬁnal volume of 1.5ml. A volume of 20 ml reconstituted Detection Antibody
Cocktail was added and the mixture was incubated for 1 h at room temperature.
After removal of array buffer 5 from the membranes, the lysate Detection Antibody
mixture was added to the membrane. The membranes were incubated at 4 C on a
rocker overnight. Each membrane was washed three times with 1 wash buffer
(20ml, 10min each) and incubated with 2ml streptavidin-HRP (1:2,000 in array
buffer 5) for 30min at room temperature on a rocker. After three repeating
washing steps with 1 wash buffer (20ml, 10min each), an ECL substrate
(Thermo Scientiﬁc) for HRP enzyme and an ECL camera (Intas, Goettingen,
Germany) were used to detect the signals. The signals were quantiﬁed with the
National Institutes of Health (NIH) ImageJ software package (freeware).
ADAM8 DI structure modelling. A BLAST (a) search of the Protein Data Bank
(b) using the ADAM8 sequence revealed the top structure hits as Russell’s viper
venom metalloproteinase (2e3x) (c) and vascular apoptosis-inducing protein-2
(2ero) (d). 2E3X and 2ERO align structurally at 2.33Å using the alignment in
Supplementary Fig. 1. The structure of ADAM10 (2AO7) (e) was also aligned even
though it was eighteenth in the BLAST results. The per cent identity matrix is
shown in Supplementary Fig. 2.
Administration of cyclic peptide BK-1361 in mice. Lyophilized cyclic peptide was
dissolved in sterile PBS to a concentration of 1 mg ml 1. Since neither an acute
(single injection) nor a chronic toxicity (repeated weekly injections over a total of 4
weeks) using a dosage of 10 mg g 1 body weight via intraperitoneal route was
observed based on organ histology after necropsy (Supplementary Fig. 9), this
dosage regimen was administered throughout the experiments presented in this
study. Equal volumes of sterile PBS were injected as control. For KPC mice, BK-
1361 injections were started at 4 weeks of age and continued for over 8 weeks. Mice
were constantly monitored and were killed when they reached end point criteria.
Orthotopic injections. Orthotopic pancreatic cancer tumours were implanted into
6-week-old female CD1 nu/nu mice. Ketamine/xylazine (100/10mg kg 1) was
used for anaesthesia. The left side of the mouse was shaved and the fur was
completely removed. The surgical area was sterilized with an iodine solution
(Povidone-iodine, Novaplus, Irving, TX, USA) and a small incision (o1 cm) was
made through the skin and abdominal wall at the base of the spleen. The spleen
was gently pulled through the incision, exposing the tail of the pancreas. The cell-
Matrigel solution (1 106 cells in 50 ml) was injected into the tail of the pancreas.
The Matrigel was allowed to set (B 10 s), the needle was gently removed from the
pancreas and the area was swabbed with iodine to devitalize any stray cells in the
injection site. The pancreas and spleen were replaced in the abdomen and the
incision site closed with 3–4 sutures (Ethilon 5–0 PS-3, Ethicon, Piscataway, NJ,
USA). The Matrigel method of orthotopic tumour implantation has resulted in
100% tumour uptake with little evidence of extra-pancreatic leakage. Panc1 and
AsPC-1 cell-derived tumours were analysed 12 days after implantation.
Statistical analysis. Invasion assays and western blot data were analysed by one-
way ANOVA. For in vivo experiments, two-way ANOVA using Shapiro–Wilk
normality was used. For pairwise comparisons of tumour weights/volumes and
tissue pathologies (acinar tissue and inﬁltration rates), including ImageJ analyses,
Tukey-type linear contrast tests were used. Survival was estimated as a Kaplan–
Meier survival curve, and the statistical analysis was carried out using a log-rank
test for the censored data. Based on the obtained results, the data were considered
not signiﬁcant (PZ0.05), signiﬁcant * (Pr0.05), highly signiﬁcant ** (Pr0.01) or
very highly signiﬁcant *** (Pr0.001).
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